These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28562582)

  • 61. Molecular Mechanisms of B Cell Antigen Gathering and Endocytosis.
    Hoogeboom R; Tolar P
    Curr Top Microbiol Immunol; 2016; 393():45-63. PubMed ID: 26336965
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.
    Young RM; Phelan JD; Wilson WH; Staudt LM
    Immunol Rev; 2019 Sep; 291(1):190-213. PubMed ID: 31402495
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.
    Liefwalker DF; Ryan M; Wang Z; Pathak KV; Plaisier S; Shah V; Babra B; Dewson GS; Lai IK; Mosley AR; Fueger PT; Casey SC; Jiang L; Pirrotte P; Swaminathan S; Sears RC
    Cancer Metab; 2021 Aug; 9(1):31. PubMed ID: 34399819
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recombination activating gene-expression in lymphoma cell lines and lymphomas.
    Knecht H
    Blood; 1995 Jul; 86(1):412-4. PubMed ID: 7795253
    [No Abstract]   [Full Text] [Related]  

  • 65. Oncogenic mechanisms in Burkitt lymphoma.
    Schmitz R; Ceribelli M; Pittaluga S; Wright G; Staudt LM
    Cold Spring Harb Perspect Med; 2014 Feb; 4(2):. PubMed ID: 24492847
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Calcineurin-independent NFATc1 signaling is essential for survival of Burkitt lymphoma cells.
    Murti K; Fender H; Glatzle C; Wismer R; Sampere-Birlanga S; Wild V; Muhammad K; Rosenwald A; Serfling E; Avots A
    Front Oncol; 2023; 13():1205788. PubMed ID: 37546418
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Malignant B cells and antigenic receptor: necessity or habit?
    Ciric B; Pease LR
    Leuk Lymphoma; 2002 Jul; 43(7):1383-90. PubMed ID: 12389617
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lymphoma and the control of B cell growth and differentiation.
    Rui L; Goodnow CC
    Curr Mol Med; 2006 May; 6(3):291-308. PubMed ID: 16712476
    [TBL] [Abstract][Full Text] [Related]  

  • 69. LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.
    Thurner L; Hartmann S; Fadle N; Kemele M; Bock T; Bewarder M; Regitz E; Neumann F; Nimmesgern A; von Müller L; Pott C; Kim YJ; Bohle RM; Wasik M; Schuster SJ; Hansmann ML; Preuss KD; Pfreundschuh M
    Leukemia; 2019 Jan; 33(1):148-158. PubMed ID: 29955130
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Generation of B lymphoma cell lines from knockout mice by transformation in vivo with an Emu-myc transgene.
    Corcoran LM; Tawfilis S; Barlow LJ
    J Immunol Methods; 1999 Aug; 228(1-2):131-8. PubMed ID: 10556550
    [TBL] [Abstract][Full Text] [Related]  

  • 71. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression.
    Irish JM; Myklebust JH; Alizadeh AA; Houot R; Sharman JP; Czerwinski DK; Nolan GP; Levy R
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):12747-54. PubMed ID: 20543139
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Gimap5-dependent inactivation of GSK3β is required for CD4
    Patterson AR; Endale M; Lampe K; Aksoylar HI; Flagg A; Woodgett JR; Hildeman D; Jordan MB; Singh H; Kucuk Z; Bleesing J; Hoebe K
    Nat Commun; 2018 Jan; 9(1):430. PubMed ID: 29382851
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Deep mutational scanning reveals transmembrane features governing surface expression of the B cell antigen receptor.
    Ramesh S; Go M; Call ME; Call MJ
    Front Immunol; 2024; 15():1426795. PubMed ID: 39108267
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Plasma membrane topography governs the 3D dynamic localization of IgM B cell antigen receptor clusters.
    Saltukoglu D; Özdemir B; Holtmannspötter M; Reski R; Piehler J; Kurre R; Reth M
    EMBO J; 2023 Feb; 42(4):e112030. PubMed ID: 36594262
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sugar-coated signaling in follicular lymphoma.
    Strout MP
    Blood; 2015 Oct; 126(16):1871-2. PubMed ID: 26472734
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting pathological B cell receptor signalling in lymphoid malignancies.
    Young RM; Staudt LM
    Nat Rev Drug Discov; 2013 Mar; 12(3):229-43. PubMed ID: 23449308
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phosphatidylserine synthesis controls oncogenic B cell receptor signaling in B cell lymphoma.
    Omi J; Kato T; Yoshihama Y; Sawada K; Kono N; Aoki J
    J Cell Biol; 2024 Feb; 223(2):. PubMed ID: 38048228
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.
    Dzikiewicz-Krawczyk A; Kok K; Slezak-Prochazka I; Robertus JL; Bruining J; Tayari MM; Rutgers B; de Jong D; Koerts J; Seitz A; Li J; Tillema B; Guikema JE; Nolte IM; Diepstra A; Visser L; Kluiver J; van den Berg A
    Leukemia; 2017 Jun; 31(6):1470-1473. PubMed ID: 28331227
    [No Abstract]   [Full Text] [Related]  

  • 79. Autoimmunity checkpoints as therapeutic targets in B cell malignancies.
    Müschen M
    Nat Rev Cancer; 2018 Feb; 18(2):103-116. PubMed ID: 29302068
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies.
    Shain KH; Tao J
    Oncogene; 2014 Aug; 33(32):4107-13. PubMed ID: 24037527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.